ZERO National Symposium 2022 - Day 2 Presentations

07 Feb 2023

The Zero Childhood Cancer Symposium 2022 held in Sydney provided a unique experience for international and national leading experts in cancer precision medicine to explore and showcase their cutting-edge progress made in the direction of curing childhood cancer through explorative, detailed, and precise developments.  

Experts from a variety of backgrounds and uniting with the goal of progressing pediatric cancer developments, explored their key reports ranging in topics such as:  

  • cancer biology and clinical translation  
  • genetics, genomics and cancer predisposition  
  • bioethics and psychosocial research 
  • functional biology and preclinical modelling 
  • learning from the lived experience - parent and consumer perspectives. 

The hybrid event held at the NSW Teachers Federation Conference center with close to 200 of the world’s researchers, clinicians and health professionals attending online and in-person, span across two days and left an audience with a message that the facilities for developing a world with all children being free from cancer is well on its way.  

Below are some of the research presentations that were held on the second day of the symposium 2022.

Pei Wang, PhD - Proteogenomic analysis of Pediatric/AYA brain tumors 

Dr Ina Oehme - Development of a functional patient-derived 3D multicellular platform for realtime personalized drug sensitivity profiling in the pediatric precision oncology program INFORM 

Professor Vanessa Tyrell - Scope and structure of an economic analysis of the use of multi-omics and pre-clinical drug screening in a high-risk paediatric cancer cohort

Macabe Daley - Lots of patients and no patience? Online self-filled family history could be an option

Leighton Schreyer - Developing a value framework for paediatric health technology assessment in Canada: A modified-delphi process to inform assessment criteria

Dr Neevika Manoharan - Choroid Plexus Carcinoma: The role of comprehensive profiling as an avenue to novel therapeutic considerations

Dr Saumya Samaraweera - Incorporating germline predisposition risk in treatment decisions for AML patients

Since its establishment in 2017, ZERO has focused on identifying new treatment options for children with high-risk cancers – those with less than 30% chance of survival. Now, the revolutionary program will be expanded so that by the end of 2023, all children and young people up to the age of 21 years in Australia who are diagnosed with cancer will have access to precision medicine through the ZERO program. 

Find out more at